Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 ...
On Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA ...
Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...
The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...
Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...
"Metastatic breast cancer is where breast cancer moves from the origin in the breast through the blood, and through the lymph ...
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
Top Forbes | SHOOK financial advisors and Wall Street investment firms have pledged more than $500,000 toward development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback